Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease
Summary
“Cardior’s RNA approach has shown an encouraging safety and efficacy profile in its initial clinical read-out and has the potential to provide a true disease modifying therapy to patients. I look forward to working with the incoming investors as we leverage the current momentum in the RNA therapy field to position Cardior for success,” said Dr. Karin Kleinhans, Partner at LSP. Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. From the early stages of a technology or life science venture, INKEF Capital supports entrepreneurs building their ideas into successful international businesses.